CSL Biopharmaceuticals

CSL Limited is a premier global biotechnology leader that develops and delivers innovative biotherapies and vaccines. The company's origins trace back to 1916 when the Commonwealth Serum Laboratories was established as an Australian government body to provide vaccines for the nation during World War I. Over the decades, CSL evolved through significant milestones, including its privatization in 1994 and the strategic acquisition of international entities like the Swiss ZLB Bioplasma AG and the German Behringwerke (founded by Nobel laureate Emil von Behring).

Today, CSL operates through its core businesses: CSL Behring, which specializes in plasma-derived and recombinant therapies; CSL Seqirus, one of the world's largest influenza vaccine providers; and CSL Vifor, a leader in iron deficiency and nephrology. Manufacturing is conducted across a global network of sophisticated facilities located in Australia, the United States, Germany, Switzerland, and the United Kingdom, ensuring a reliable supply of life-saving medicines to patients in more than 100 countries.